These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9145209)

  • 21. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
    Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
    Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
    Tsukuda K; Sakurada M; Niki I; Oka Y; Kikuchi M
    Horm Metab Res; 1998 Jan; 30(1):42-9. PubMed ID: 9503038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
    McLeod JF
    Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.
    Kataoka Y; Yasuda S; Miyamoto Y; Sase K; Kosuge M; Kimura K; Yoshimasa Y; Miyazaki S;
    Circ J; 2012; 76(3):712-20. PubMed ID: 22240597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
    Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
    Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.
    Kleist P; Ehrlich A; Suzuki Y; Timmer W; Wetzelsberger N; Lücker PW; Fuder H
    Eur J Clin Pharmacol; 1997; 53(2):149-52. PubMed ID: 9403288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulating activity of A-4166 on insulin release in in situ hamster pancreatic perfusion.
    Seto Y; Fujita H; Dan K; Fujita T; Kato R
    Pharmacology; 1995 Oct; 51(4):245-53. PubMed ID: 8577818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
    Hu S
    Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
    Hirose T; Mizuno R; Yoshimoto T
    Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
    Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
    Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
    de Souza CJ; Gagen K; Chen W; Dragonas N
    Diabetes Obes Metab; 2001 Apr; 3(2):85-95. PubMed ID: 11298730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs.
    Misawa K; Ichikawa K; Ojima K; Hamano S; Kitamura T; Komatsu H
    Pharmacology; 2001 Feb; 62(2):65-72. PubMed ID: 11174074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats.
    Ohta T; Furukawa N; Yonemori F; Wakitani K
    Eur J Pharmacol; 1999 Feb; 367(1):91-9. PubMed ID: 10082270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.
    Mori A; Lee P; Yamashita T; Nishimaki Y; Oda H; Saeki K; Miki Y; Mizutani H; Ishioka K; Honjo T; Arai T; Sako T
    Vet Res Commun; 2009 Dec; 33(8):957-70. PubMed ID: 19728131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.